Q2 2026 Revolution Medicines Inc Earnings Call Transcript
Key Points
- Revolution Medicines Inc (RVMD) reported paradigm-changing clinical results from the Phase 3 RASolute 302 study, showing statistically significant improvements in overall survival, progression-free survival, and quality of life for daraxonrasib in previously treated metastatic pancreatic cancer.
- The company's expanded access program (EAP) has been highly successful, providing daraxonrasib to over 2,000 eligible patients across nearly all US states, with more than 90% of requests approved.
- The FDA has accepted the New Drug Application (NDA) for daraxonrasib in pancreatic cancer, and the EMA has initiated a phase review under its Cancer Medicines Pathfinder project, potentially accelerating regulatory timelines.
- Early clinical data for zoldonrasib in first-line pancreatic cancer showed compelling antitumor activity, with objective response rates of 82% and 61% when combined with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel, respectively.
- In non-small cell lung cancer, both zoldonrasib and elironrasib demonstrated highly encouraging antitumor activity in combination with pembrolizumab and chemotherapy, with objective response rates of 82% and 85%, respectively, supporting the initiation of registrational trials RASolve 308 and 307.
- The company ended Q2 2026 with a strong cash position of $3.9 billion, including proceeds from a $2.2 billion capital raise and a $250 million royalty tranche, providing ample financial flexibility.
- The company reported a significant increase in net loss for Q2 2026, reaching $644 million compared to $248 million in the same period last year, driven by higher operating expenses and a noncash charge related to warrant fair value changes.
- R&D and G&A expenses increased substantially year-over-year, with R&D expenses rising to $395 million from $224 million and G&A expenses rising to $110 million from $41 million, reflecting aggressive investment in pipeline and commercial readiness.
- The company updated its 2026 GAAP operating expense guidance upward to between $2.1 billion and $2.2 billion, indicating higher-than-expected spending on manufacturing, clinical development, and commercial infrastructure.
- There is a potential risk of crossover in the Phase 3 frontline pancreatic cancer trials (RASolute 303), as patients in the control arm may drop out to receive commercial daraxonrasib upon approval, potentially confounding overall survival analyses.
- The company acknowledged that it lacks quantitative feedback from the expanded access program, making it difficult to assess real-world performance of daraxonrasib outside of clinical trials.
- Management declined to provide specific details on the data shared with the FDA to support breakthrough therapy designation for daraxonrasib in non-small cell lung cancer, leaving some uncertainty about the strength of the evidence.
Good day and thank you for standing by. Welcome to the Revolution Medicines Q2 2026 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Ryan Asay, Senior Vice President, Corporate Affairs. Please go ahead.
Thank you, and welcome, everyone, to the second quarter 2026 earnings call. Joining me on today's call are Dr. Mark Goldsmith, Revolution Medicines' Chairman and Chief Executive Officer; Dr. Alan Sandler, our Chief Development Officer; and Jack Anders, our Chief Financial Officer; Dr. Wei Lin, our Chief Medical Officer; and Anthony Mancini, our Chief Global Commercialization Officer, will join us for the Q&A portion of today's call.
We would like to inform you that certain statements we make during this call will be forward-looking because such statements deal with future events and are subject to many risks and uncertainties. Actual
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
